INT4260

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1975
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 29
Total Number 29
Disease Relevance 4.39
Pain Relevance 19.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Npr1) intracellular (Npr1)
Anatomy Link Frequency
paw 2
bladder 2
amygdala 2
Npr1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 57 100.00 Very High Very High Very High
Morphine 25 100.00 Very High Very High Very High
Enkephalin 15 100.00 Very High Very High Very High
Serotonin 13 100.00 Very High Very High Very High
Pain 6 100.00 Very High Very High Very High
amygdala 2 100.00 Very High Very High Very High
Clonidine 7 99.98 Very High Very High Very High
c fibre 4 99.92 Very High Very High Very High
IPN 9 99.84 Very High Very High Very High
opioid receptor 17 99.80 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pain 5 100.00 Very High Very High Very High
Bordatella Infection 8 98.36 Very High Very High Very High
Hyperalgesia 14 98.16 Very High Very High Very High
Uremia 45 97.24 Very High Very High Very High
Diabetes Mellitus 16 95.48 Very High Very High Very High
Pressure And Volume Under Development 32 93.72 High High
Vibrio Infection 3 89.92 High High
Urological Neuroanatomy 1 87.48 High High
Neuropathic Pain 3 83.40 Quite High
Opiate Addiction 2 77.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The bladder and urethral activities during the rhythmic bladder contractions were evaluated before and after the intraarterial administration of methylene blue, which prevents the activation of soluble guanylate cyclase.
Negative_regulation (prevents) of Positive_regulation (activation) of guanylate cyclase in bladder
1) Confidence 0.43 Published 1992 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 1306609 Disease Relevance 0 Pain Relevance 0
We conclude that local application of drugs generating a low NO concentration reduces incision pain through activation of guanylate cyclase.
Negative_regulation (reduces) of Positive_regulation (activation) of cyclase associated with pain
2) Confidence 0.25 Published 2002 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12007920 Disease Relevance 0.56 Pain Relevance 0.58
This decrease in adenylate cyclase activity induced by acute in vivo morphine or clonidine, which persists in isolated membranes after the removal of the drugs, may be an early step in the sequence of events that leads to the development of opiate or clonidine addiction in the LC.
Negative_regulation (decrease) of Positive_regulation (induced) of cyclase associated with addiction, locus ceruleus, opiate, clonidine and morphine
3) Confidence 0.22 Published 1989 Journal Mol. Pharmacol. Section Abstract Doc Link 2498635 Disease Relevance 0.09 Pain Relevance 1.68
Stimulation of collicular adenylate cyclase by serotonin was significantly but incompletely blocked by serotonin antagonists, including d-lysergic acid diethylamide (d-LSD), 2-bromo-d-lysergic acid diethylamide, methysergide, 1-methyl-8 beta-carbobenzyloxy-aminomethyl-10 alpha-ergoline and cyproheptadine.
Negative_regulation (blocked) of Positive_regulation (Stimulation) of cyclase associated with antagonist and serotonin
4) Confidence 0.21 Published 1975 Journal Brain Res. Section Abstract Doc Link 1078637 Disease Relevance 0 Pain Relevance 0.66
Local administration of agents which inhibit the formation of nitric oxide (NG-monomethyl-L-arginine) or inhibit the activation of guanylate cyclase by nitric oxide (methylene blue) abolished diclofenac-induced analgesia.
Negative_regulation (inhibit) of Positive_regulation (activation) of cyclase associated with diclofenac and analgesia
5) Confidence 0.16 Published 1994 Journal Eur. J. Pharmacol. Section Abstract Doc Link 7908638 Disease Relevance 0.42 Pain Relevance 1.39
Stimulation of adenylate cyclase by PMA is markedly reduced following EGTA treatment, is not observed when adenyl-5'-yl-imidodiphosphate is substituted for ATP as substrate for adenylate cyclase, and is enhanced by L-alpha-phosphatidyl-L-serine.
Negative_regulation (reduced) of Positive_regulation (Stimulation) of cyclase
6) Confidence 0.13 Published 1986 Journal J. Neurochem. Section Abstract Doc Link 3734803 Disease Relevance 0.08 Pain Relevance 0.18
Furthermore, prenalterol produced a concentration-dependent inhibition of isoprenaline-activated adenylate cyclase.
Negative_regulation (inhibition) of Positive_regulation (isoprenaline-activated) of cyclase
7) Confidence 0.12 Published 1982 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 6121296 Disease Relevance 0 Pain Relevance 0.43
Treatment with a D2 receptor antagonist (eticlopride; 1 mg/kg/day) for 7 days reduced D1 receptor stimulation of adenylyl cyclase.
Negative_regulation (reduced) of Positive_regulation (stimulation) of cyclase associated with antagonist
8) Confidence 0.12 Published 1997 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 9353370 Disease Relevance 0 Pain Relevance 0.92
This activation of adenylate-cyclase is blocked, locally, by opiates.
Negative_regulation (blocked) of Positive_regulation (activation) of cyclase associated with opiate
9) Confidence 0.11 Published 1981 Journal Agents Actions Section Abstract Doc Link 6280466 Disease Relevance 0.36 Pain Relevance 0.36
In control animals, the mu-opioid selective agonists, sufentanil and DAMGO, stimulated [35S]5'-(gamma-thio)-triphosphate ([35S]GTP gamma S) binding and inhibited forskolin-stimulated adenylyl cyclase activity, through a mechanism involving pertussis toxin (PTX) sensitive G alpha(i/o) subunits.
Negative_regulation (inhibited) of Positive_regulation (forskolin-stimulated) of cyclase associated with bordatella infection, agonist and opioid
10) Confidence 0.10 Published 2008 Journal Neuropharmacology Section Abstract Doc Link 18384820 Disease Relevance 0.17 Pain Relevance 1.04
Seven days of chronic sufentanil treatment developed antinociceptive tolerance associated with a reduction in mu-agonist-induced [35S]GTP gamma S binding, mu-agonist-induced adenylyl cyclase inhibition, and co-precipitation of G alpha o, G alpha i2 G alpha z and G alpha q11 subunits with mu-opioid receptors.
Negative_regulation (inhibition) of Positive_regulation (mu-agonist-induced) of cyclase associated with mu opioid receptor, agonist, tolerance and antinociceptive
11) Confidence 0.10 Published 2008 Journal Neuropharmacology Section Abstract Doc Link 18384820 Disease Relevance 0.17 Pain Relevance 1.06
Clonidine inhibited the activation of adenylate cyclase by IPN in AH13O cells.
Negative_regulation (inhibited) of Positive_regulation (activation) of cyclase associated with ipn and clonidine
12) Confidence 0.09 Published 1986 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 2879059 Disease Relevance 0.07 Pain Relevance 0.98
In contrast, the purported kappa-opioid receptor agonist bremazocine (3-300 nM) inhibited the stimulated adenylate cyclase activity to a similar extent as did [D-Ala2-MePhe4,Gly-ol5]enkephalin and DPDPE.
Negative_regulation (inhibited) of Positive_regulation (stimulated) of cyclase associated with agonist, kappa opioid receptor and enkephalin
13) Confidence 0.09 Published 1989 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2543814 Disease Relevance 0 Pain Relevance 1.27
The peripheral antinociceptive effect of diazoxide was not prevented by prior administration of naloxone (12.5, 25 and 50 microg/paw), an opioid receptor antagonist, or methylene blue (75, 125 and 300 microg/paw), an agent that inhibits the activation of guanylate cyclase by nitric oxide.
Negative_regulation (inhibits) of Positive_regulation (activation) of cyclase in paw associated with antagonist, narcan, opioid receptor and antinociceptive
14) Confidence 0.09 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15063156 Disease Relevance 0.18 Pain Relevance 0.64
It is suggested that guanosine 5'-O-(2-thiodiphosphate), 2',5'-dideoxyadenosine and Walsh inhibitor protein inhibited prostaglandin E2 sensitization of primary afferent C-fibres by inhibiting a stimulatory guanine nucleotide-binding regulatory protein, adenylyl cyclase, and protein kinase A, respectively.
Negative_regulation (inhibiting) of Positive_regulation (stimulatory) of cyclase associated with c fibre
15) Confidence 0.09 Published 1996 Journal Neuroscience Section Abstract Doc Link 8834407 Disease Relevance 0 Pain Relevance 0.32
The results indicate that opioids, by activating mu- or delta-, but not kappa-opioid receptors may cause a profound inhibition of adenylate cyclase activity stimulated by activation of (postsynaptic) D-1 DA receptors upon the (presynaptic) release of DA.
Negative_regulation (inhibition) of Positive_regulation (stimulated) of cyclase associated with dopamine, kappa opioid receptor and opioid
16) Confidence 0.07 Published 1989 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2543814 Disease Relevance 0 Pain Relevance 1.07
The morphine-increased adenylate cyclase activity in amygdala was reversed by the chronic intra-accumbens microinjections of H7 and H8.
Negative_regulation (reversed) of Positive_regulation (morphine-increased) of cyclase in amygdala associated with amygdala and morphine
17) Confidence 0.04 Published 1996 Journal Eur. J. Neurosci. Section Abstract Doc Link 8996817 Disease Relevance 0.13 Pain Relevance 1.30
The CB1 agonist desacetyllevonantradol inhibited forskolin-stimulated adenylyl cyclase (18% and 36% maximal inhibition; EC50 = 160 and 73 nM, in rats and monkeys, respectively) and the CB1 antagonist SR141716A (10 microM) completely blocked the maximal inhibition.
Negative_regulation (inhibited) of Positive_regulation (forskolin-stimulated) of cyclase associated with antagonist and agonist
18) Confidence 0.04 Published 2001 Journal Neuropharmacology Section Abstract Doc Link 11378162 Disease Relevance 0 Pain Relevance 0.38
The D2 agonist quinelorane inhibited forskolin (10 microM)-stimulated adenylyl cyclase in a dose-dependent manner (26% and 20% maximal inhibition; EC50 = 2 and 0.5 microM, in rats and monkeys, respectively) and maximal inhibition was completely blocked by the D2 antagonist sulpiride (10 microM).
Negative_regulation (inhibition) of Positive_regulation (-stimulated) of cyclase associated with antagonist and agonist
19) Confidence 0.04 Published 2001 Journal Neuropharmacology Section Abstract Doc Link 11378162 Disease Relevance 0 Pain Relevance 0.38
The D2 agonist quinelorane inhibited forskolin (10 microM)-stimulated adenylyl cyclase in a dose-dependent manner (26% and 20% maximal inhibition; EC50 = 2 and 0.5 microM, in rats and monkeys, respectively) and maximal inhibition was completely blocked by the D2 antagonist sulpiride (10 microM).
Negative_regulation (inhibited) of Positive_regulation (-stimulated) of cyclase associated with antagonist and agonist
20) Confidence 0.04 Published 2001 Journal Neuropharmacology Section Abstract Doc Link 11378162 Disease Relevance 0 Pain Relevance 0.34

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox